AU712606B2 - Combined use of interleukin-10 and cyclosporin for immunosuppression therapy - Google Patents
Combined use of interleukin-10 and cyclosporin for immunosuppression therapy Download PDFInfo
- Publication number
- AU712606B2 AU712606B2 AU68422/96A AU6842296A AU712606B2 AU 712606 B2 AU712606 B2 AU 712606B2 AU 68422/96 A AU68422/96 A AU 68422/96A AU 6842296 A AU6842296 A AU 6842296A AU 712606 B2 AU712606 B2 AU 712606B2
- Authority
- AU
- Australia
- Prior art keywords
- interleukin
- medicament
- individual
- cyclosporin
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US205795P | 1995-08-09 | 1995-08-09 | |
US60/002057 | 1995-08-09 | ||
US61995896A | 1996-03-20 | 1996-03-20 | |
US08/619958 | 1996-03-20 | ||
PCT/US1996/012538 WO1997005896A1 (fr) | 1995-08-09 | 1996-08-06 | Utilisation combinee d'interleukine-10 et de cyclosporine pour une therapie immunosuppressive |
Publications (2)
Publication Number | Publication Date |
---|---|
AU6842296A AU6842296A (en) | 1997-03-05 |
AU712606B2 true AU712606B2 (en) | 1999-11-11 |
Family
ID=26669861
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU68422/96A Ceased AU712606B2 (en) | 1995-08-09 | 1996-08-06 | Combined use of interleukin-10 and cyclosporin for immunosuppression therapy |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0845994A1 (fr) |
JP (1) | JPH11510806A (fr) |
AU (1) | AU712606B2 (fr) |
CA (1) | CA2228379A1 (fr) |
WO (1) | WO1997005896A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1864999A (en) * | 1997-12-15 | 1999-07-05 | Universite Laval | Methods and compositions for improving the success of cell transplantation in a host |
EP1000626A1 (fr) * | 1998-09-18 | 2000-05-17 | Applied Research Systems ARS Holding N.V. | Antagoniste de récepteur de chemokine et cyclosporine en thérapie combinée |
JP3135532B2 (ja) | 1998-09-29 | 2001-02-19 | 松下電送システム株式会社 | ネットワークファクシミリ装置 |
US6577712B2 (en) | 2000-04-07 | 2003-06-10 | Telefonaktiebolaget Lm Ericsson (Publ) | Distributed voice mail system |
AU2002952492A0 (en) * | 2002-11-06 | 2002-11-21 | Cbio Limited | Chaperonin 10 immunosuppression |
MX2016005614A (es) | 2013-11-01 | 2016-12-09 | Spherium Biomed S L | Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos. |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994008606A1 (fr) * | 1992-10-01 | 1994-04-28 | Schering Corporation | Utilisation de l'il-10 dans la prevention ou le traitement des diabetes sucres non insulino-dependants |
WO1994017773A2 (fr) * | 1993-02-01 | 1994-08-18 | Université Libre de Bruxelles | Utilisation d'une composition pharmaceutique comprenant une dose efficace d'interleukine-10, d'un analogue et/ou d'un agoniste d'interleukine-10 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ249754A (en) * | 1992-03-04 | 1997-06-24 | Schering Corp | Interleukin-10 and its use in inhibiting graft vs host disease or tissue rejection |
-
1996
- 1996-08-06 JP JP9508515A patent/JPH11510806A/ja active Pending
- 1996-08-06 EP EP96928798A patent/EP0845994A1/fr not_active Ceased
- 1996-08-06 WO PCT/US1996/012538 patent/WO1997005896A1/fr not_active Application Discontinuation
- 1996-08-06 AU AU68422/96A patent/AU712606B2/en not_active Ceased
- 1996-08-06 CA CA002228379A patent/CA2228379A1/fr not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994008606A1 (fr) * | 1992-10-01 | 1994-04-28 | Schering Corporation | Utilisation de l'il-10 dans la prevention ou le traitement des diabetes sucres non insulino-dependants |
WO1994017773A2 (fr) * | 1993-02-01 | 1994-08-18 | Université Libre de Bruxelles | Utilisation d'une composition pharmaceutique comprenant une dose efficace d'interleukine-10, d'un analogue et/ou d'un agoniste d'interleukine-10 |
Also Published As
Publication number | Publication date |
---|---|
CA2228379A1 (fr) | 1997-02-20 |
AU6842296A (en) | 1997-03-05 |
JPH11510806A (ja) | 1999-09-21 |
EP0845994A1 (fr) | 1998-06-10 |
WO1997005896A1 (fr) | 1997-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2087525C (fr) | Immunotherapie adoptive au moyen de l'interleukine 7 | |
US9301979B2 (en) | Method for attenuating immune response using mesenchymal stem cells and cytokines | |
EP2931877B1 (fr) | Procédés permettant la modulation de l'effet immunorégulateur des cellules souches | |
US6165785A (en) | Bone marrow cultures for developing suppressor and stimulator cells for research and therapeutic applications | |
US11872250B2 (en) | Methods for inducing an immune response by administering activated mesenchymal stem cells | |
CA2253803A1 (fr) | Utilisation d'interleukine-10 pour produire une population de lymphocytes suppresseurs | |
Mastino et al. | Combination therapy with thymosin α1 potentiates the anti‐tumor activity of interleukin‐2 with cyclophosphamide in the treatment of the lewis lung carcinoma in mice | |
DE69320967T2 (de) | Unterdrückung der t-zell proliferation mittels peptidfragmenten des myelin basischen protein | |
US20090142317A1 (en) | Process for reducing effects of graft versus host disease using ex vivo expanded cd4+cd25+ regulatory t cells | |
Ramírez et al. | Induction of resistance to active experimental allergic encephalomyelitis by myelin basic protein‐specific Th2 cell lines generated in the presence of glucocorticoids and IL‐4 | |
WO1993017698A1 (fr) | Utilisation d'interleukine-10 pour supprimer des maladies provoquees par la reaction du greffon contre l'hote | |
AU712606B2 (en) | Combined use of interleukin-10 and cyclosporin for immunosuppression therapy | |
US6022536A (en) | Combined use of interleukin 10 and cyclosporin for immunosuppression therapy | |
Keever et al. | Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4. | |
EP3307298B1 (fr) | Composition multi-peptidique | |
KR101488224B1 (ko) | 면역학적 질병의 치료를 위한 티모신 알파 1의 용도 | |
MXPA98001091A (en) | Combined use of interleukin-10 and cyclosporine for immunosupres therapy | |
EP0561927B1 (fr) | Compositions pharmaceutiques destinees au traitement des affections malignes a lymphocytes b | |
Wei et al. | Lymphokine-activated killer cell regulation of T-cell-mediated immunity to Candida albicans | |
US20240269188A1 (en) | Methods for inducing an immune response by administering activated mesenchymal stem cells | |
Frankel et al. | Immunotherapy of acute myeloid leukemia | |
Degauque et al. | TIM-1 PATHWAY CONSTITUTE A NEW “FIRST SIGNAL PATHWAY” FOR T CELL. | |
Mouse | Increased Antitumor Effects Using IL-2 with | |
Kloosterman | Graft-versus-leukemia: applicable in the treatment of leukemia with bone marrow transplantation?: preclinical studies in rat models relevant for human acute leukemia | |
Chung | Roles of IL-7 in T cell development and mature T lymphocytes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |